Table 1 Synopsis of the updated ATP III LDL-C Goals and Cut-points for TLC and Drug Therapy in Different Risk Categories and Proposed Modifications Based on Recent Clinical Trial Evidence
From: The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia
Risk Category | Goal | TLC | Drug Therapy |
|---|---|---|---|
High risk: CHD or CHD risk equivalents (10-year risk >20%) | < 100 mg/dL (optional goal: <70 mg/dL) | ≥ 100 mg/dL | ≥ 100 (<100 mg/dL: consider drug options) |
Moderately high risk: 2+ risk factors (10-year risk 10% to 20%) | < 130 mg/dL | ≥ 130 mg/dL | ≥ 130 mg/dL(100–129 mg/dL; consider drug options) |
Moderate risk: 2+ risk factors (10-year risk <10%) | < 130 mg/dL | ≥ 130 mg/dL | ≥ 160 mg/dL |
Lower risk: 0–1 risk factor | < 160 mg/dL | ≥ 160 mg/dL | ≥ 190 mg/dL (160–189 mg/dL: LDL-lowering drug optional) |